U.S. markets closed

Aravive, Inc. (ARAV)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
4.1600+0.1400 (+3.48%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Price Crosses Moving Average

Price Crosses Moving Average

Previous Close4.0200
Open4.0500
Bid4.1300 x 800
Ask4.1800 x 800
Day's Range4.0500 - 4.3200
52 Week Range3.6300 - 9.9500
Volume129,591
Avg. Volume148,857
Market Cap86.17M
Beta (5Y Monthly)3.08
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Aravive, Inc.
    Analyst Report: Eli Lilly and CompanyEli Lilly is a drug firm with a focus on neuroscience, endocrinology, oncology, and immunology. Lilly's key products include Alimta and Verzenio for cancer; Jardiance, Trulicity, Humalog, and Humulin for diabetes; and Taltz and Olumiant for immunology.
    Rating
    Fair Value
    Economic Moat
    5 days agoMorningstar
View more
All
News
Press Releases